257 related articles for article (PubMed ID: 37064123)
1. NF-kB and the CLL microenvironment.
O'Donnell A; Pepper C; Mitchell S; Pepper A
Front Oncol; 2023; 13():1169397. PubMed ID: 37064123
[TBL] [Abstract][Full Text] [Related]
2. NF-κB activation in chronic lymphocytic leukemia: A point of convergence of external triggers and intrinsic lesions.
Mansouri L; Papakonstantinou N; Ntoufa S; Stamatopoulos K; Rosenquist R
Semin Cancer Biol; 2016 Aug; 39():40-8. PubMed ID: 27491692
[TBL] [Abstract][Full Text] [Related]
3. Regulation of Bcl-XL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLL.
Haselager M; Thijssen R; West C; Young L; Van Kampen R; Willmore E; Mackay S; Kater A; Eldering E
Cell Death Differ; 2021 May; 28(5):1658-1668. PubMed ID: 33495554
[TBL] [Abstract][Full Text] [Related]
4. The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-κB activation and induces apoptosis in chronic lymphocytic leukemia B cells.
Godbersen JC; Humphries LA; Danilova OV; Kebbekus PE; Brown JR; Eastman A; Danilov AV
Clin Cancer Res; 2014 Mar; 20(6):1576-89. PubMed ID: 24634471
[TBL] [Abstract][Full Text] [Related]
5. Microenvironmental stromal cells abrogate NF-κB inhibitor-induced apoptosis in chronic lymphocytic leukemia.
Simon-Gabriel CP; Foerster K; Saleem S; Bleckmann D; Benkisser-Petersen M; Thornton N; Umezawa K; Decker S; Burger M; Veelken H; Claus R; Dierks C; Duyster J; Zirlik K
Haematologica; 2018 Jan; 103(1):136-147. PubMed ID: 29122993
[TBL] [Abstract][Full Text] [Related]
6. BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF-κB Nuclear Translocation.
Asslaber D; Wacht N; Leisch M; Qi Y; Maeding N; Hufnagl C; Jansko B; Zaborsky N; Villunger A; Hartmann TN; Greil R; Egle A
Clin Cancer Res; 2019 Mar; 25(6):1901-1912. PubMed ID: 30487125
[TBL] [Abstract][Full Text] [Related]
7. JAK-STAT signalling shapes the NF-κB response in CLL towards venetoclax sensitivity or resistance via Bcl-XL.
Haselager MV; Thijssen R; Bax D; Both D; De Boer F; Mackay S; Dubois J; Mellink C; Kater AP; Eldering E
Mol Oncol; 2023 Jun; 17(6):1112-1128. PubMed ID: 36550750
[TBL] [Abstract][Full Text] [Related]
8. BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway.
Endo T; Nishio M; Enzler T; Cottam HB; Fukuda T; James DF; Karin M; Kipps TJ
Blood; 2007 Jan; 109(2):703-10. PubMed ID: 16973958
[TBL] [Abstract][Full Text] [Related]
9. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells.
Furman RR; Asgary Z; Mascarenhas JO; Liou HC; Schattner EJ
J Immunol; 2000 Feb; 164(4):2200-6. PubMed ID: 10657675
[TBL] [Abstract][Full Text] [Related]
10. NF-κB-p62-NRF2 survival signaling is associated with high ROR1 expression in chronic lymphocytic leukemia.
Sanchez-Lopez E; Ghia EM; Antonucci L; Sharma N; Rassenti LZ; Xu J; Sun B; Kipps TJ; Karin M
Cell Death Differ; 2020 Jul; 27(7):2206-2216. PubMed ID: 31992855
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of NF-κB-mediated signaling by the cyclin-dependent kinase inhibitor CR8 overcomes prosurvival stimuli to induce apoptosis in chronic lymphocytic leukemia cells.
Cosimo E; McCaig AM; Carter-Brzezinski LJ; Wheadon H; Leach MT; Le Ster K; Berthou C; Durieu E; Oumata N; Galons H; Meijer L; Michie AM
Clin Cancer Res; 2013 May; 19(9):2393-405. PubMed ID: 23532892
[TBL] [Abstract][Full Text] [Related]
12. The proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-κB response in chronic lymphocytic leukemia cells.
Gupta SV; Hertlein E; Lu Y; Sass EJ; Lapalombella R; Chen TL; Davis ME; Woyach JA; Lehman A; Jarjoura D; Byrd JC; Lucas DM
Clin Cancer Res; 2013 May; 19(9):2406-19. PubMed ID: 23515408
[TBL] [Abstract][Full Text] [Related]
13. Chronic lymphocytic leukemia cells in a lymph node microenvironment depict molecular signature associated with an aggressive disease.
Mittal AK; Chaturvedi NK; Rai KJ; Gilling-Cutucache CE; Nordgren TM; Moragues M; Lu R; Opavsky R; Bociek GR; Weisenburger DD; Iqbal J; Joshi SS
Mol Med; 2014 Jul; 20(1):290-301. PubMed ID: 24800836
[TBL] [Abstract][Full Text] [Related]
14. Aberrant splicing of the tumor suppressor CYLD promotes the development of chronic lymphocytic leukemia via sustained NF-κB signaling.
Hahn M; Bürckert JP; Luttenberger CA; Klebow S; Hess M; Al-Maarri M; Vogt M; Reißig S; Hallek M; Wienecke-Baldacchino A; Buch T; Muller CP; Pallasch CP; Wunderlich FT; Waisman A; Hövelmeyer N
Leukemia; 2018 Jan; 32(1):72-82. PubMed ID: 28566736
[TBL] [Abstract][Full Text] [Related]
15. NF-kappaB as a therapeutic target in chronic lymphocytic leukemia.
Lopez-Guerra M; Colomer D
Expert Opin Ther Targets; 2010 Mar; 14(3):275-88. PubMed ID: 20148715
[TBL] [Abstract][Full Text] [Related]
16. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.
Herishanu Y; Pérez-Galán P; Liu D; Biancotto A; Pittaluga S; Vire B; Gibellini F; Njuguna N; Lee E; Stennett L; Raghavachari N; Liu P; McCoy JP; Raffeld M; Stetler-Stevenson M; Yuan C; Sherry R; Arthur DC; Maric I; White T; Marti GE; Munson P; Wilson WH; Wiestner A
Blood; 2011 Jan; 117(2):563-74. PubMed ID: 20940416
[TBL] [Abstract][Full Text] [Related]
17. NOD2 silencing promotes cell apoptosis and inhibits drug resistance in chronic lymphocytic leukemia by inhibiting the NF-κB signaling pathway.
Zheng C; Zhu Z; Weng S; Zhang Q; Fu Y; Cai X; Liu Z; Shi Y
J Biochem Mol Toxicol; 2023 Dec; 37(12):e23510. PubMed ID: 37700718
[TBL] [Abstract][Full Text] [Related]
18. Novel pyrrolobenzodiazepine benzofused hybrid molecules inhibit NF-κB activity and synergise with bortezomib and ibrutinib in hematological cancers.
Lewis T; Corcoran DB; Thurston DE; Giles PJ; Ashelford K; Walsby EJ; Fegan CD; Pepper AGS; Miraz Rahman K; Pepper C
Haematologica; 2021 Apr; 106(4):958-967. PubMed ID: 32381576
[TBL] [Abstract][Full Text] [Related]
19. Expression and Activity of the NF-κB Subunits in Chronic Lymphocytic Leukaemia: A Role for RelB and Non-Canonical Signalling.
Mulligan EA; Tudhope SJ; Hunter JE; Clift AEG; Elliott SL; Summerfield GP; Wallis J; Pepper CJ; Durkacz B; Veuger S; Willmore E
Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835430
[TBL] [Abstract][Full Text] [Related]
20. miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors.
Sharma S; Pavlasova GM; Seda V; Cerna KA; Vojackova E; Filip D; Ondrisova L; Sandova V; Kostalova L; Zeni PF; Borsky M; Oppelt J; Liskova K; Kren L; Janikova A; Pospisilova S; Fernandes SM; Shehata M; Rassenti LZ; Jaeger U; Doubek M; Davids MS; Brown JR; Mayer J; Kipps TJ; Mraz M
Blood; 2021 May; 137(18):2481-2494. PubMed ID: 33171493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
